Form 4: Teva Pharmaceutical Director Reports Routine Equity Compensation Activity, Including RSU Vesting and New Grant

A Teva Pharmaceutical Industries Ltd. director, Ronit Satchi-Fainaro, reported the vesting of previously granted restricted share units (RSUs) and the acquisition of new RSUs as part of her compensation.

Summary

• Ronit Satchi-Fainaro, a Director at Teva Pharmaceutical Industries Ltd. (TEVA), reported changes in her beneficial ownership of company securities.
• On June 6, 2025, 9,632 Restricted Share Units (RSUs) granted on June 6, 2024, vested, converting into 9,632 Ordinary Shares.
• Following this vesting, Ms. Satchi-Fainaro directly beneficially owns 97,909 Ordinary Shares.
• Additionally, on June 5, 2025, Ms. Satchi-Fainaro was granted 14,492 new Restricted Share Units.
• These newly granted RSUs are scheduled to vest on June 5, 2026.
• Each RSU represents a contingent right to receive one ordinary share or its cash equivalent at the discretion of the Human Resources and Compensation Committee.

Sentiment

Score: 6

Explanation: The document reports routine, expected insider transactions related to compensation. The vesting of RSUs and the grant of new ones are generally positive as they align director interests with shareholders, but they do not indicate extraordinary performance or significant strategic shifts.

Positives

• The vesting of RSUs indicates the fulfillment of prior compensation agreements, aligning director interests with long-term company performance.
• The grant of new RSUs demonstrates continued commitment to the director and serves as an incentive for future performance and retention.

Future Outlook

The grant of new Restricted Share Units with a vesting date in June 2026 indicates a continued long-term incentive structure for the director, aligning her interests with the company's future performance.

Industry Context

This Form 4 filing details routine equity compensation for a director, which is a common practice across publicly traded companies in the pharmaceutical and other industries to align management and director interests with shareholder value.

Related Party Transactions

• The reported RSU grants and vesting represent compensation transactions between the company and a director, which are a form of related party transaction.

Stakeholder Impact

• Shareholders: The equity compensation aligns the director's financial interests with the long-term performance of the company's stock, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The 14,492 Restricted Share Units granted on June 5, 2025, are expected to vest on June 5, 2026.

Key Dates

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, Insider Transaction, Restricted Share Units, RSU, Equity Compensation, Beneficial Ownership, Director Compensation